EUVIMEDEUVIMED entdecken
Editorial

Percutaneous coronary interventions versus coronary artery bypass graft surgery in coronary artery disease

David P Taggart

Vascular Pharmacology · 2024-06 · 155 · 107367

DOI: 10.1016/j.vph.2024.107367 ↗

Kurz gefasst

Editorial in der Zeitschrift Vascular Pharmacology, 2024-06. Verfasst von David P Taggart. Beteiligte Einrichtung: Cardiovascular Surgery, Nuffield Dept of Surgical Sciences, University of Oxford, John Radcliffe Hospital, United Kingdom. Electronic address: david.…. Hauptthemen laut MEDLINE: Coronary Artery Bypass, Coronary Artery Disease, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The evidence basis for percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in coronary artery disease (CAD) has become more firmly established over the last decade in view of new evidence from several large, randomized trials and propensity-matched registries. In comparison to PCI, CABG offers substantial survival benefits and significant reductions in myocardial infarction and need for repeat revascularization in multivessel disease in patients with intermediate and high severity disease, whereas for left main disease these benefits are largely observed in patients with the highest-severity disease. In general, the benefits of CABG are further enhanced in patients with diabetes and/or impaired ventricular function. In stable or urgent clinical situations most decisions for intervention should be agreed by a multidisciplinary group ('Heart Team'), incorporating the severity of CAD and the patient's overall clinical suitability and personal wishes for any proposed procedure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery BypassCoronary Artery DiseasePercutaneous Coronary InterventionHumansClinical Decision-MakingMyocardial InfarctionPatient SelectionRandomized Controlled Trials as TopicRisk FactorsSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

CABGCoronary artery bypass graftingDiabetesHeart team/Multidisciplinary teamImpaired ventricular functionLeft main diseaseMultivessel diseasePCIPercutaneous coronary intervention

Autor:innen und Institutionen

  • Cardiovascular Surgery, Nuffield Dept of Surgical Sciences, University of Oxford, John Radcliffe Hospital, United Kingdom. Electronic address: david.taggart@ouh.nhs.uk.

Zitieren

APA

Taggart, D. P. (2024). Percutaneous coronary interventions versus coronary artery bypass graft surgery in coronary artery disease. Vascular Pharmacology, 155, 107367. https://doi.org/10.1016/j.vph.2024.107367

Vancouver

Taggart DP. Percutaneous coronary interventions versus coronary artery bypass graft surgery in coronary artery disease. Vascular Pharmacology. 2024;155:107367. doi:10.1016/j.vph.2024.107367

BibTeX
@article{Taggart2024,
  author = {Taggart, David P},
  title = {Percutaneous coronary interventions versus coronary artery bypass graft surgery in coronary artery disease},
  journal = {Vascular Pharmacology},
  year = {2024},
  volume = {155},
  pages = {107367},
  doi = {10.1016/j.vph.2024.107367}
}
Kostenlos starten →